Advanced Search

Project: Opioid Treatments for Chronic Pain

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Extraction Form for Key Questions 1-4 Azrah Ahmed 1, 2, 3, 4


Associated Studies (each link opens a new tab)

Title Author Year
A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. Adams EH., Breiner S., Cicero TJ., Geller A., Inciardi JA., Schnoll SH., Senay EC., Woody GE. 2006
A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. Adler L., McDonald C., O'Brien C., Wilson M. 2002
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Afilalo M., Etropolski MS., Kuperwasser B., Kelly K., Okamoto A., Van Hove I., Steup A., Lange B., Rauschkolb C., Haeussler J. 2010
Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). Akbik H., Butler SF., Budman SH., Fernandez K., Katz NP., Jamison RN. 2006
Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Allan L., Hays H., Jensen NH., de Waroux BL., Bolt M., Donald R., Kalso E. 2001
Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Allan L., Richarz U., Simpson K., Slappendel R. 2005
Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-naïve patients with chronic pain. Arai T., Kashimoto Y., Ukyo Y., Tominaga Y., Imanaka K. 2015
The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Ashburn MA., Slevin KA., Messina J., Xie F. 2011
Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. Babul N., Noveck R., Chipman H., Roth SH., Gana T., Albert K. 2004
Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial. Baron R., Jansen JP., Binder A., Pombo-Suarez M., Kennes L., Müller M., Falke D., Steigerwald I. 2016
Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. Baron R., Likar R., Martin-Mola E., Blanco FJ., Kennes L., Müller M., Falke D., Steigerwald I. 2016
Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study. Baron R., Martin-Mola E., Müller M., Dubois C., Falke D., Steigerwald I. 2015
Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Beaulieu AD., Peloso PM., Haraoui B., Bensen W., Thomson G., Wade J., Quigley P., Eisenhoffer J., Harsanyi Z., Darke AC. -- Not Found --
Risk of adverse events in patients prescribed long-term opioids: A cohort study in the UK Clinical Practice Research Datalink. Bedson J., Chen Y., Ashworth J., Hayward RA., Dunn KM., Jordan KP. 2019
A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Binsfeld H., Szczepanski L., Waechter S., Richarz U., Sabatowski R. -- Not Found --
A Clinical Trial Comparing Tapering Doses of Buprenorphine with Steady Doses for Chronic Pain and Co-existent Opioid Addiction. Blondell RD., Ashrafioun L., Dambra CM., Foschio EM., Zielinski AL., Salcedo DM. 2010
A Detailed Exploration Into the Association of Prescribed Opioid Dosage and Overdose Deaths Among Patients With Chronic Pain. Bohnert AS., Logan JE., Ganoczy D., Dowell D. 2016
Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Boureau F., Legallicier P., Kabir-Ahmadi M. 2003
A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Breivik H., Ljosaa TM., Stengaard-Pedersen K., Persson J., Aro H., Villumsen J., Tvinnemose D. 2010
A comparison of the analgesic efficacy of Tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. Burch F., Fishman R., Messina N., Corser B., Radulescu F., Sarbu A., Craciun-Nicodin MM., Chiriac R., Beaulieu A., Rodrigues J., Beignot-Devalmont P., Duplan A., Robertson S., Fortier L., Bouchard S. 2007
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Buynak R., Shapiro DY., Okamoto A., Van Hove I., Rauschkolb C., Steup A., Lange B., Lange C., Etropolski M. 2010
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Buynak R., Shapiro DY., Okamoto A., Van Hove I., Rauschkolb C., Steup A., Lange B., Lange C., Etropolski M. 2010
Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. Caldwell JR., Hale ME., Boyd RE., Hague JM., Iwan T., Shi M., Lacouture PG. 1999
Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. Caldwell JR., Rapoport RJ., Davis JC., Offenberg HL., Marker HW., Roth SH., Yuan W., Eliot L., Babul N., Lynch PM. 2002
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Campbell G., Hall WD., Peacock A., Lintzeris N., Bruno R., Larance B., Nielsen S., Cohen M., Chan G., Mattick RP., Blyth F., Shanahan M., Dobbins T., Farrell M., Degenhardt L. 2018
The association of opioid use with incident lower extremity fractures in spinal cord injury. Carbone LD., Chin AS., Lee TA., Burns SP., Svircev JN., Hoenig HM., Akhigbe T., Weaver FM. 2013
Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Carman WJ., Su S., Cook SF., Wurzelmann JI., McAfee A. 2011
Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Christoph A., Eerdekens MH., Kok M., Volkers G., Freynhagen R. 2017
Analgesic tolerance without demonstrable opioid-induced hyperalgesia: a double-blinded, randomized, placebo-controlled trial of sustained-release morphine for treatment of chronic nonradicular low-back pain. Chu LF., D'Arcy N., Brady C., Zamora AK., Young CA., Kim JE., Clemenson AM., Angst MS., Clark JD. 2012
Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study. Chung CP., Dupont WD., Murray KT., Hall K., Stein CM., Ray WA. 2019
Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Cloutier C., Taliano J., O'Mahony W., Csanadi M., Cohen G., Sutton I., Sinclair D., Awde M., Henein S., Robinson L., Eisenhoffer J., Piraino PS., Harsanyi Z., Michalko KJ. -- Not Found --
Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. Coffin PO., Behar E., Rowe C., Santos GM., Coffa D., Bald M., Vittinghoff E. 2016
Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. DeLemos BP., Xiang J., Benson C., Gana TJ., Pascual ML., Rosanna R., Fleming B. 2011
Prescription opioids for back pain and use of medications for erectile dysfunction. Deyo RA., Smith DH., Johnson ES., Tillotson CJ., Donovan M., Yang X., Petrik A., Morasco BJ., Dobscha SK. 2013
Opioid prescriptions for chronic pain and overdose: a cohort study. Dunn KM., Saunders KW., Rutter CM., Banta-Green CJ., Merrill JO., Sullivan MD., Weisner CM., Silverberg MJ., Campbell CI., Psaty BM., Von Korff M. 2010
The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Edlund MJ., Martin BC., Russo JE., DeVries A., Braden JB., Sullivan MD. 2014
Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. Fiellin DA., Schottenfeld RS., Cutter CJ., Moore BA., Barry DT., O'Connor PG. 2014
Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD). Fishman RL., Kistler CJ., Ellerbusch MT., Aparicio RT., Swami SS., Shirley ME., Jain AK., Fortier L., Robertson S., Bouchard S. -- Not Found --
Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. Frank B., Serpell MG., Hughes J., Matthews JN., Kapur D. 2008
Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. Friedmann N., Klutzaritz V., Webster L. -- Not Found --
Health-Related Quality-of-Life Outcomes in Patients Treated with Push-Pull OROS Hydromorphone versus Extended-Release Oxycodone for Chronic Hip or Knee Osteoarthritis Pain: A Randomized, Open-Label, Parallel-Group, Multicenter Study. Gajria K., Kosinski M., Schein J., Kavanagh S., Dubois D. 2008
Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Gana TJ., Pascual ML., Fleming RR., Schein JR., Janagap CC., Xiang J., Vorsanger GJ. 2006
Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Gatti A., Sabato AF., Occhioni R., Colini Baldeschi G., Reale C. 2009
Morphine, gabapentin, or their combination for neuropathic pain. Gilron I., Bailey JM., Tu D., Holden RR., Weaver DF., Houlden RL. 2005
Combination of morphine with nortriptyline for neuropathic pain. Gilron I., Tu D., Holden RR., Jackson AC., DuMerton-Shore D. 2015
Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. Gimbel J., Spierings EL., Katz N., Xiang Q., Tzanis E., Finn A. 2016
Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Gimbel JS., Richards P., Portenoy RK. 2003
Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study. Gomes T., Greaves S., van den Brink W., Antoniou T., Mamdani MM., Paterson JM., Martins D., Juurlink DN. 2018
Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. Gomes T., Juurlink DN., Antoniou T., Mamdani MM., Paterson JM., van den Brink W. 2017
Opioid dose and drug-related mortality in patients with nonmalignant pain. Gomes T., Mamdani MM., Dhalla IA., Paterson JM., Juurlink DN. 2011
Opioid dose and risk of road trauma in Canada: a population-based study. Gomes T., Redelmeier DA., Juurlink DN., Dhalla IA., Camacho X., Mamdani MM. 2013
Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Gordon A., Callaghan D., Spink D., Cloutier C., Dzongowski P., O'Mahony W., Sinclair D., Rashiq S., Buckley N., Cohen G., Kim J., Boulanger A., Piraino PS., Eisenhoffer J., Harsanyi Z., Darke AC., Michalko KJ. 2010
Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Gordon A., Rashiq S., Moulin DE., Clark AJ., Beaulieu AD., Eisenhoffer J., Piraino PS., Quigley P., Harsanyi Z., Darke AC. -- Not Found --
Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Hale M., Khan A., Kutch M., Li S. 2010
Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Hale M., Tudor IC., Khanna S., Thipphawong J. 2007
Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Hale M., Upmalis D., Okamoto A., Lange C., Rauschkolb C. 2009
Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. Hale ME., Ahdieh H., Ma T., Rauck R. 2007
Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain. Hale ME., Laudadio C., Yang R., Narayana A., Malamut R. 2015
Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain. Hale ME., Zimmerman TR., Eyal E., Malamut R. -- Not Found --
Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Hanna M., O'Brien C., Wilson MC. 2008
Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Harati Y., Gooch C., Swenson M., Edelman S., Greene D., Raskin P., Donofrio P., Cornblath D., Sachdeo R., Siu CO., Kamin M. 1998
Rates of adverse events of long-acting opioids in a state Medicaid program. Hartung DM., Middleton L., Haxby DG., Koder M., Ketchum KL., Chou R. 2007
Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries. Hernandez I., He M., Brooks MM., Zhang Y. 2018
Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial. Hooten WM., Warner DO. 2015
The effect of opioids on phantom limb pain and cortical reorganization. Huse E., Larbig W., Flor H., Birbaumer N. 2001
Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial. Hwang CJ., Lee JH., Kim JH., Min SH., Park KW., Seo HY., Song KS. 2019
Mortality After Discontinuation of Primary Care-Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study. James JR., Scott JM., Klein JW., Jackson S., McKinney C., Novack M., Chew L., Merrill JO. 2019
Opioid therapy for chronic noncancer back pain. A randomized prospective study. Jamison RN., Raymond SA., Slawsby EA., Nedeljkovic SS., Katz NP. 1998
Further validation of an opioid risk assessment tool: the Brief Risk Interview. Jones T., Lookatch S., Grant P., McIntyre J., Moore T. -- Not Found --
Validation of a new risk assessment tool: the Brief Risk Questionnaire. Jones T., Lookatch S., Moore T. -- Not Found --
Preliminary data on a new opioid risk assessment measure: the Brief Risk Interview. Jones T., Moore T. -- Not Found --
A comparison of various risk screening methods in predicting discharge from opioid treatment. Jones T., Moore T., Levy JL., Daffron S., Browder JH., Allen L., Passik SD. 2012
Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Karlsson M., Berggren AC. 2009
Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Katz N., Hale M., Morris D., Stauffer J. 2010
A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Katz N., Kopecky EA., OʼConnor M., Brown RH., Fleming AB. 2015
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Katz N., Rauck R., Ahdieh H., Ma T., Gerritsen van der Hoop R., Kerwin R., Podolsky G. 2007
Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study. Kawamata M., Iseki M., Kawakami M., Yabuki S., Sasaki T., Ishida M., Nishiyori A., Hida H., Kikuchi SI. 2019
Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Khoromi S., Cui L., Nackers L., Max MB. 2007
Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study. Kjaersgaard-Andersen P., Nafei A., Skov O., Madsen F., Andersen HM., Krøner K., Hvass I., Gjøderum O., Pedersen L., Branebjerg PE. 1990
Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial. Kopecky EA., Vaughn B., Lagasse S., O'Connor M. 2017
Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain. Krebs EE., Becker WC., Zerzan J., Bair MJ., McCoy K., Hui S. 2011
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. Krebs EE., Gravely A., Nugent S., Jensen AC., DeRonne B., Goldsmith ES., Kroenke K., Bair MJ., Noorbaloochi S. 2018
Association of Opioids with Falls, Fractures, and Physical Performance among Older Men with Persistent Musculoskeletal Pain. Krebs EE., Paudel M., Taylor BC., Bauer DC., Fink HA., Lane NE., Ensrud KE. 2016
Tapering off long-term opioid therapy in chronic non-cancer pain patients: A randomized clinical trial. Kurita GP., Højsted J., Sjøgren P. 2018
Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Langford R., McKenna F., Ratcliffe S., Vojtassák J., Richarz U. 2006
Effectiveness and Safety of Transdermal Buprenorphine Versus Sustained-release Tramadol in Patients With Moderate to Severe Musculoskeletal Pain: An 8-Week, Randomized, Double-Blind, Double-Dummy, Multicenter, Active-controlled, Noninferiority Study. Leng X., Li Z., Lv H., Zheng Y., Liu Y., Dai K., Yao C., Yan X., Zeng X. 2015
Opioid use for noncancer pain and risk of myocardial infarction amongst adults. Li L., Setoguchi S., Cabral H., Jick S. 2013
Opioid use for noncancer pain and risk of fracture in adults: a nested case-control study using the general practice research database. Li L., Setoguchi S., Cabral H., Jick S. 2013
One Month of Oral Morphine Decreases Gray Matter Volume in the Right Amygdala of Individuals with Low Back Pain: Confirmation of Previously Reported Magnetic Resonance Imaging Results. Lin JC., Chu LF., Stringer EA., Baker KS., Sayyid ZN., Sun J., Campbell KA., Younger JW. 2016
Analgesic use and risk of recurrent falls in participants with or at risk of knee osteoarthritis: data from the Osteoarthritis Initiative. Lo-Ciganic WH., Floden L., Lee JK., Ashbeck EL., Zhou L., Chinthammit C., Purdy AW., Kwoh CK. 2017
Opioid medication discontinuation and risk of adverse opioid-related health care events. Mark TL., Parish W. 2019
Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Markenson JA., Croft J., Zhang PG., Richards P. -- Not Found --
Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone. Markman J., Meske DS., Kopecky EA., Vaughn B., O'Connor ML., Passik SD. 2018
Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Matsumoto AK., Babul N., Ahdieh H. -- Not Found --
Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. Mayorga AJ., Wang S., Kelly KM., Thipphawong J. 2016
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Miller K., Yarlas A., Wen W., Dain B., Lynch SY., Brennan MJ., Ripa SR. 2013
The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health. Miller K., Yarlas A., Wen W., Dain B., Lynch SY., Ripa SR., Pergolizzi JV., Raffa R. 2014
Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. Miller M., Barber CW., Leatherman S., Fonda J., Hermos JA., Cho K., Gagnon DR. 2015
Opioid analgesics and the risk of fractures in older adults with arthritis. Miller M., Stürmer T., Azrael D., Levin R., Solomon DH. 2011
A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Mitra F., Chowdhury S., Shelley M., Williams G. 2013
A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Moore TM., Jones T., Browder JH., Daffron S., Passik SD. 2009
Randomised trial of oral morphine for chronic non-cancer pain. Moulin DE., Iezzi A., Amireh R., Sharpe WK., Boyd D., Merskey H. 1996
A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis. Munera C., Drehobl M., Sessler NE., Landau C. -- Not Found --
Hydromorphone extended release for neuropathic and non-neuropathic/nociceptive chronic low back pain: a post hoc analysis of data from a randomized, multicenter, double-blind, placebo-controlled clinical trial. Nalamachu S., Hale M., Khan A. -- Not Found --
A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. Naliboff BD., Wu SM., Schieffer B., Bolus R., Pham Q., Baria A., Aragaki D., Van Vort W., Davis F., Shekelle P. 2011
A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. Neumann AM., Blondell RD., Jaanimägi U., Giambrone AK., Homish GG., Lozano JR., Kowalik U., Azadfard M. 2013
Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Nicholson B., Ross E., Sasaki J., Weil A. 2006
Opioid treatment of painful chronic pancreatitis. Niemann T., Madsen LG., Larsen S., Thorsgaard N. 2000
Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Niesters M., Proto PL., Aarts L., Sarton EY., Drewes AM., Dahan A. 2014
Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Norrbrink C., Lundeberg T. -- Not Found --
The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. O'Donnell JB., Ekman EF., Spalding WM., Bhadra P., McCabe D., Berger MF. -- Not Found --
Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Pavelka K., Pelisková Z., Stehlíková H., Ratcliffe S., Repas C. 1998
All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population. Peckham AM., Fairman KA., Sclar DA. 2018
A randomized, double-blind, double-dummy comparison of short- and long-acting dihydrocodeine in chronic non-malignant pain. Pedersen L., Borchgrevink PC., Breivik HP., Fredheim OM. 2014
Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. Peloso PM., Bellamy N., Bensen W., Thomson GT., Harsanyi Z., Babul N., Darke AC. 2000
Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Portenoy RK., Messina J., Xie F., Peppin J. 2007
Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Raja SN., Haythornthwaite JA., Pappagallo M., Clark MR., Travison TG., Sabeen S., Royall RM., Max MB. 2002
Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis. Rauck R., Rapoport R., Thipphawong J. 2013
A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial. Rauck RL., Bookbinder SA., Bunker TR., Alftine CD., Gershon S., de Jong E., Negro-Vilar A., Ghalie R. -- Not Found --
The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. Rauck RL., Bookbinder SA., Bunker TR., Alftine CD., Ghalie R., Negro-Vilar A., de Jong E., Gershon S. -- Not Found --
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment. Rauck RL., Hale ME., Bass A., Bramson C., Pixton G., Wilson JG., Setnik B., Meisner P., Sommerville KW., Malhotra BK., Wolfram G. 2015
Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. Rauck RL., Nalamachu S., Wild JE., Walker GS., Robinson CY., Davis CS., Farr SJ. 2014
Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Rauck RL., Potts J., Xiang Q., Tzanis E., Finn A. 2016
Out-of-hospital mortality among patients receiving methadone for noncancer pain. Ray WA., Chung CP., Murray KT., Cooper WO., Hall K., Stein CM. 2015
Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain. Ray WA., Chung CP., Murray KT., Hall K., Stein CM. 2016
Increased risk of reproductive dysfunction in women prescribed long-term opioids for musculoskeletal pain: A matched cohort study in the Clinical Practice Research Datalink. Richardson E., Bedson J., Chen Y., Lacey R., Dunn KM. 2018
Management of Neuropathic Chronic Pain with Methadone Combined with Ketamine: A Randomized, Double Blind, Active-Controlled Clinical Trial. Rigo FK., Trevisan G., Godoy MC., Rossato MF., Dalmolin GD., Silva MA., Menezes MS., Caumo W., Ferreira J. 2017
Oral opioid therapy for chronic peripheral and central neuropathic pain. Rowbotham MC., Twilling L., Davies PS., Reisner L., Taylor K., Mohr D. 2003
Association Between Commonly Prescribed Opioids and Androgen Deficiency in Men: A Retrospective Cohort Analysis. Rubinstein AL., Carpenter DM. 2017
Efficacy of tramadol in treatment of pain in fibromyalgia. Russell IJ., Kamin M., Bennett RM., Schnitzer TJ., Green JA., Katz WA. 2000
Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? Salzman RT., Roberts MS., Wild J., Fabian C., Reder RF., Goldenheim PD. 1999
Relationship of opioid use and dosage levels to fractures in older chronic pain patients. Saunders KW., Dunn KM., Merrill JO., Sullivan M., Weisner C., Braden JB., Psaty BM., Von Korff M. 2010
Prescription Opioid Duration, Dose, and Increased Risk of Depression in 3 Large Patient Populations. Scherrer JF., Salas J., Copeland LA., Stock EM., Ahmedani BK., Sullivan MD., Burroughs T., Schneider FD., Bucholz KK., Lustman PJ. -- Not Found --
The influence of prescription opioid use duration and dose on development of treatment resistant depression. Scherrer JF., Salas J., Sullivan MD., Schneider FD., Bucholz KK., Burroughs T., Copeland L., Ahmedani B., Lustman PJ. 2016
Efficacy of tramadol in treatment of chronic low back pain. Schnitzer TJ., Gray WL., Paster RZ., Kamin M. 2000
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Schwartz S., Etropolski M., Shapiro DY., Okamoto A., Lange R., Haeussler J., Rauschkolb C. 2011
Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. Serrie A., Lange B., Steup A. 2017
Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Simpson DM., Messina J., Xie F., Hale M. 2007
Transdermal Buprenorphine Relieves Neuropathic Pain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Diabetic Peripheral Neuropathic Pain. Simpson RW., Wlodarczyk JH. 2016
Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy. Sindrup SH., Konder R., Lehmann R., Meier T., Winkel M., Ashworth J., Baron R., Jensen TS. 2012
The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Sindrup SH., Madsen C., Brøsen K., Jensen TS. 1999
Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. Steiner D., Munera C., Hale M., Ripa S., Landau C. 2011
Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. Steiner DJ., Sitar S., Wen W., Sawyerr G., Munera C., Ripa SR., Landau C. 2011
Prescription Opioid Taper Support for Outpatients With Chronic Pain: A Randomized Controlled Trial. Sullivan MD., Turner JA., DiLodovico C., D'Appollonio A., Stephens K., Chan YF. 2017
Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. Sun EC., Dixit A., Humphreys K., Darnall BD., Baker LC., Mackey S. 2017
Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study. Taipale H., Hamina A., Karttunen N., Koponen M., Tanskanen A., Tiihonen J., Hartikainen S., Tolppanen AM. 2019
Outpatient treatment of prescription opioid dependence: comparison of two methods. Tennant FS., Rawson RA. 1982
A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. Thorne C., Beaulieu AD., Callaghan DJ., O'Mahony WF., Bartlett JM., Knight R., Kraag GR., Akhras R., Piraino PS., Eisenhoffer J., Harsanyi Z., Darke AC. -- Not Found --
Methodological Issues in Conducting Pilot Trials in Chronic Pain as Randomized, Double-blind, Placebo-controlled Studies. Tominaga Y., Koga H., Uchida N., Wanibe M., Hirose K., Matsumura T., Okamoto A., Richarz U., Etropolski M. 2016
Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. Trenkwalder C., Chaudhuri KR., Martinez-Martin P., Rascol O., Ehret R., Vališ M., Sátori M., Krygowska-Wajs A., Marti MJ., Reimer K., Oksche A., Lomax M., DeCesare J., Hopp M. 2015
Comparison of two methodologies to measure agricultural occupational fatalities. Murphy DJ., Seltzer BL., Yesalis CE. 1990
Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice. Ueberall MA., Eberhardt A., Mueller-Schwefe GH. 2016
Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids. Ueberall MA., Mueller-Schwefe GH. 2015
Effectiveness of Opioids for Chronic Noncancer Pain: A Two-Year Multicenter, Prospective Cohort Study With Propensity Score Matching. Veiga DR., Monteiro-Soares M., Mendonça L., Sampaio R., Castro-Lopes JM., Azevedo LF. 2019
Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. Vigil JM., Stith SS., Adams IM., Reeve AP. 2017
A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Vinik AI., Shapiro DY., Rauschkolb C., Lange B., Karcher K., Pennett D., Etropolski MS. 2014
A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee. Vojtaššák J., Vojtaššák J., Jacobs A., Rynn L., Waechter S., Richarz U. 2011
Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Vondrackova D., Leyendecker P., Meissner W., Hopp M., Szombati I., Hermanns K., Ruckes C., Weber S., Grothe B., Fleischer W., Reimer K. 2008
Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Vorsanger G., Xiang J., Jordan D., Farrell J. 2007
Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. Vorsanger G., Xiang J., Okamoto A., Upmalis D., Moskovitz B. -- Not Found --
Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. Vorsanger GJ., Xiang J., Gana TJ., Pascual ML., Fleming RR. -- Not Found --
Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Watson CP., Babul N. 1998
Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Watson CP., Moulin D., Watt-Watson J., Gordon A., Eisenhoffer J. 2003
Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. Webster LR., Butera PG., Moran LV., Wu N., Burns LH., Friedmann N. 2006
Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Webster LR., Slevin KA., Narayana A., Earl CQ., Yang R. 2013
Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Webster LR., Webster RM. -- Not Found --
A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain. Wen W., Sitar S., Lynch SY., He E., Ripa SR. 2015
Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Wild JE., Grond S., Kuperwasser B., Gilbert J., McCann B., Lange B., Steup A., Häufel T., Etropolski MS., Rauschkolb C., Lange R. -- Not Found --
Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Wu CL., Agarwal S., Tella PK., Klick B., Clark MR., Haythornthwaite JA., Max MB., Raja SN. 2008
A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain. Yarlas A., Miller K., Wen W., Dain B., Lynch SY., Pergolizzi JV., Raffa RB., Ripa SR. 2013
A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression. Yarlas A., Miller K., Wen W., Lynch SY., Munera C., Dain B., Pergolizzi JV., Raffa R., Ripa SR. 2016
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. Yarlas A., Miller K., Wen W., Lynch SY., Munera C., Pergolizzi JV., Raffa R., Ripa SR. 2015
A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Zin CS., Nissen LM., O'Callaghan JP., Duffull SB., Smith MT., Moore BJ. 2010
Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial Fleischmann RM, Caldwell JR, Roth SH, et al. 2001
MST continuous tablets and pain control in severe rheumatoid arthritis Moran C. 1991




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/